作者
Chris JLM Meijer, Johannes Berkhof, Philip E Castle, Albertus T Hesselink, Eduardo L Franco, Guglielmo Ronco, Marc Arbyn, F Xavier Bosch, Jack Cuzick, Joakim Dillner, Daniëlle AM Heideman, Peter JF Snijders
发表日期
2009/2/1
期刊
International journal of cancer
卷号
124
期号
3
页码范围
516-520
出版商
Wiley Subscription Services, Inc., A Wiley Company
简介
Given the strong etiologic link between high‐risk HPV infection and cervical cancer high‐risk HPV testing is now being considered as an alternative for cytology‐based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high‐risk HPV is not inherently useful unless it is informative for the presence of high‐grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high‐risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high‐grade CIN and cervical cancer to minimize redundant or excessive follow‐up procedures for high‐risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high‐risk HPV testing by hybrid capture 2 and GP5+/6+‐PCR …
引用总数
200920102011201220132014201520162017201820192020202120222023202430475255756860495558665949465138
学术搜索中的文章